Skip to main content
Premium Trial:

Request an Annual Quote

Myriad Proteomics Buys a TimeLogic DeCypher

NEW YORK, June 3 -- Myriad Proteomics has purchased a DeCypher bioinformatics system from Time Logic, the companies said today.


Myriad Proteomics, a private company based in Salt Lake City, will use the field programmable gate array-based system to help analyze protein interaction data it generates with yeast-two-hybrid and mass spectrometry experiments.


The system will help the company's researchers "piece together hundreds of thousands of DNA fragments to identify where in the human genome the interacting sequences can be mapped to and what alternatively spliced form they are in," said Jake Yue Chen, head of computational proteomics at Myriad Proteomics.


According to Myriad Proteomics, the DeCypher system, implemented within a Sun V880 server, reduced the time required for hidden Markov model searches from nine hours to less than five minutes.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.